MAINZ BIOMED B.V.
We are a molecular genetics cancer diagnostic company formed in 2021 to acquire PharmGenomics GmbH (“PharmGenomics“) with the purpose of commercializing their product portfolio in Europe and the United States. PharmGenomics has developed several IVD tests for the European market since it was founded in 2008. Our portfolio includes ColoAlert, a colorectal cancer (“CRC”) screening stool DNA […]
October 29, 2021 Read More